Xeris Biopharma Holdings, Inc. XERS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $314.85M+7.9% | $291.85M+9.7% | $266.14M+8.2% | $246.03M+10.5% | $222.55M+9.6% | ||
| $44.42M+4.3% | $42.57M+3.6% | $41.1M-5.9% | $43.7M+10.4% | $39.59M+7.5% | ||
| $32.2M+3.3% | $31.17M+6.1% | $29.38M+5.7% | $27.79M+9.0% | $25.49M-0.3% | ||
| $191.5M+5.0% | $182.37M+4.2% | $175.01M+0.9% | $173.52M+2.6% | $169.12M+3.4% | ||
| $278.95M+4.5% | $266.95M+4.1% | $256.34M+0.2% | $255.85M+4.4% | $245.04M+3.5% | ||
| $35.9M+44.2% | $24.9M+206% | $8.12M+171% | -$11.5M+52.4% | -$24.17M+31.6% | ||
| 11.4%+2.9pp | 8.5%+5.5pp | 3.1%+7.7pp | -4.7%+6.2pp | -10.9%+6.5pp | ||
| $28.66M-1.4% | $29.08M-1.9% | $29.63M-1.7% | $30.15M-2.0% | $30.76M+0.9% | ||
| -$23.89M+1.8% | -$24.34M+4.3% | -$25.44M+0.2% | -$25.5M-1.4% | -$25.16M-7.3% | ||
| $0— | $0— | $0+100% | -$3.32M-29.1% | -$2.58M-13.5% | ||
| $12.01M+2,068% | $554K+104% | -$15.64M+51.1% | -$32M+29.0% | -$45.08M+17.8% | ||
| 3.8%+3.6pp | 0.2%+6.1pp | -5.9%+7.1pp | -13%+7.2pp | -20.3%+6.7pp | ||
| $0.07+504,403,158,265,495,500% | $0.00+100% | -$0.10+52.4% | -$0.21+30.0% | -$0.30+21.1% | ||
| $37.24M+42.1% | $26.21M+178% | $9.41M+192% | -$10.24M+55.4% | -$22.95M+32.7% | ||
| 11.8%+2.8pp | 9%+5.4pp | 3.5%+7.7pp | -4.2%+6.2pp | -10.3%+6.5pp | ||
| $35.9M+44.2% | $24.9M+206% | $8.12M+171% | -$11.5M+52.4% | -$24.17M+31.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s revenue?
- Xeris Biopharma Holdings, Inc. (XERS) generated $314.9M in revenue over the trailing twelve months, up 41.5% year over year.
- Is Xeris Biopharma Holdings, Inc. profitable?
- Xeris Biopharma Holdings, Inc. reported $12.0M in net income over the trailing twelve months, a 3.8% net margin.
- What are Xeris Biopharma Holdings, Inc.'s profit margins?
- Gross margin is 85.9% and operating margin is 11.4%, with a 3.8% net margin.
- What is Xeris Biopharma Holdings, Inc.'s earnings per share?
- Xeris Biopharma Holdings, Inc.'s diluted EPS over the trailing twelve months is $0.07.
- Where does Xeris Biopharma Holdings, Inc.'s income statement data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
